enoxaparin

Inc. Sanofi sued the Food and Drug Administration in late July after the FDA gave Sandoz approval to make the generic form of the special heparin, called enoxaparin, which is used in cardiovascular ailments.

Judge Refuses to Block Generic Lovenox 2010

Both groups will receive open label enoxaparin or unfractionated heparin for at least five days and up to 12 days, followed by double-blind warfarin or edoxaban 60 mg once-daily.

FinanzNachrichten.de: Aktuelle Nachrichten 2010

Both groups will receive open label enoxaparin or unfractionated heparin for at least five days and up to 12 days, followed by double-blind warfarin or Edoxaban 60mg once-daily.

New Statesman 2010

↑ Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

Citizendium, the Citizens' Compendium - Recent changes [en] 2008

In one of the other studies, called Adopt, apixiban, an anticoagulant in the same class as rivaroxaban that is being developed by Pfizer Inc. and Bristol-Myers Squibb, failed to outperform an older drug called enoxaparin in preventing venous thromboembolism, or VTE, in patients who had extended hospital stays for other conditions.

J&J Drug May Have New Role Ron Winslow 2011

The rapid-acting heparin, which carries the generic name enoxaparin, serves an expanding market of consumers with heart disease and obesity-related diabetes.

Sanofi Seeks to Halt Lovenox Generic 2010

On July 23, the FDA granted approval to Momenta to make the special heparin called enoxaparin, while Amphastar's application remains on hold.

Baxter Faces New Challenge in Heparin Suit 2010

The drug, also known by the generic name enoxaparin, is a rapid-acting form of heparin, a widely used blood thinner.

FDA Approves Generic Lovenox 2010

Data submitted to the FDA included four main clinical studies that looked at more than 12,000 patients and in most cases studied rivaroxaban in comparison with enoxaparin, which is sold by Sanofi-Aventis SA as Lovenox.

Anticlotting Drug Faces Panel Vote 2009

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial PMID 18582928. (this trial compared rivaroxaban to short-term enoxaparin

Citizendium, the Citizens' Compendium - Recent changes [en] 2009